European Society for Medical Oncology Preceptorship on Metastatic Bladder and Kidney Cancer Lugano 2023

Description

+ Include: 37 videos + 38 pdfs, size: 1.83 GB

+ Target Audience: oncologist

+ Sample video: contact me for sample video

+ Information:

+ Topics:

ESMO-Preceptorship-on-Metastatic-Bladder-and-Kidney-Cancer-2023-Lugano-Programme.pdf
Session 1 Approaches to Upper Tract UC.mp4
Session 1 Approaches to Upper Tract UC.pdf
Session 1 Localized and Systemic Standard Treatments in Non-Muscle-Invasive Bladder Cancer Localized Treatments.mp4
Session 1 Localized and Systemic Standard Treatments in Non-Muscle-Invasive Bladder Cancer Localized Treatments.pdf
Session 1 Localized and Systemic Standard Treatments in Non-Muscle-Invasive Bladder Cancer Surgery.mp4
Session 1 Localized and Systemic Standard Treatments in Non-Muscle-Invasive Bladder Cancer Surgery.pdf
Session 1 New Treatments and Approaches to NMIBC.mp4
Session 1 New Treatments and Approaches to NMIBC.pdf
Session 2 Debate Adjuvant Chemotherapy or Immune Therapy for MIBC Adjuvant Chemotherapy.mp4
Session 2 Debate Adjuvant Chemotherapy or Immune Therapy for MIBC Adjuvant Chemotherapy.pdf
Session 2 Debate Adjuvant Chemotherapy or Immune Therapy for MIBC Immune Therapy.mp4
Session 2 Debate Adjuvant Chemotherapy or Immune Therapy for MIBC Immune Therapy.pdf
Session 2 Established and Novel Neoadjuvant Treatments for MIBC.mp4
Session 2 Established and Novel Neoadjuvant Treatments for MIBC.pdf
Session 2 First Line Treatment in Advanced Bladder Cancer.mp4
Session 2 First Line Treatment in Advanced Bladder Cancer.pdf
Session 2 Participants Clinical Case Discussion A Perioperative High Grade Lymphoepithelioma-Like Bladder Cancer Treated With Neoadjuvant Anti-PD1+CT A Clinical Case.mp4
Session 2 Participants Clinical Case Discussion A Perioperative High Grade Lymphoepithelioma-Like Bladder Cancer Treated With Neoadjuvant Anti-PD1+CT A Clinical Case.pdf
Session 2 Participants Clinical Case Discussion Complication of Neo-Adjuvant Non-Standard Immunotherapy What Can We Learn.mp4
Session 2 Participants Clinical Case Discussion Complication of Neo-Adjuvant Non-Standard Immunotherapy What Can We Learn.pdf
Session 2 Participants Clinical Case Discussion Cutaneous Toxicities Management of Enfortumab Vedotin in Metastatic Urothelial Carcinoma Two Clinical Cases.mp4
Session 2 Participants Clinical Case Discussion Cutaneous Toxicities Management of Enfortumab Vedotin in Metastatic Urothelial Carcinoma Two Clinical Cases.pdf
Session 2 Sequencing Therapy in Advanced Bladder Cancer.mp4
Session 2 Sequencing Therapy in Advanced Bladder Cancer.pdf
Session 3 Is There a Role for Nephrectomy in Advanced disease.mp4
Session 3 Is There a Role for Nephrectomy in Advanced disease.pdf
Session 3 Neoadjuvant and Adjuvant Treatment in RCC.mp4
Session 3 Neoadjuvant and Adjuvant Treatment in RCC.pdf
Session 3 Participants Clinical Case Discussion Belzutifan with Lenvatinib in VHL Associated Renal Cell Cancer.mp4
Session 3 Participants Clinical Case Discussion Belzutifan with Lenvatinib in VHL Associated Renal Cell Cancer.pdf
Session 3 Participants Clinical Case Discussion Characterising Spontaneous Regression in Metastatic ccRCC.mp4
Session 3 Participants Clinical Case Discussion Characterising Spontaneous Regression in Metastatic ccRCC.pdf
Session 3 Participants Clinical Case Discussion Papillary Renal Cell Carcinoma What is The Best Therapeutic Sequencing.mp4
Session 3 Participants Clinical Case Discussion Papillary Renal Cell Carcinoma What is The Best Therapeutic Sequencing.pdf
Session 3 Participants Clinical Case Discussion Sarcoid-Like Reaction During Adjuvant Therapy with Immune Checkpoint Inhibitors for Papillary Renal Carcinoma.mp4
Session 3 Participants Clinical Case Discussion Sarcoid-Like Reaction During Adjuvant Therapy with Immune Checkpoint Inhibitors for Papillary Renal Carcinoma.pdf
Session 3 Surgery and Other Techniques for Primary Tumour.mp4
Session 3 Surgery and Other Techniques for Primary Tumour.pdf
Session 3 The Role of Metastasectomy and SBRT in RCC.mp4
Session 3 The Role of Metastasectomy and SBRT in RCC.pdf
Session 4 Biology and Treatment of Non-Clear RCC.mp4
Session 4 Biology and Treatment of Non-Clear RCC.pdf
Session 4 Debate Immune Combinations or VEGF PD1 Inhibition as 1st Line Therapy for Advanced Clear Cell RCC Immune Combinations.mp4
Session 4 Debate Immune Combinations or VEGF PD1 Inhibition as 1st Line Therapy for Advanced Clear Cell RCC Immune Combinations.pdf
Session 4 Debate Immune Combinations or VEGF PD1 Inhibition as 1st Line Therapy for Advanced Clear Cell RCC VEGF PD1 Inhibition.mp4
Session 4 Debate Immune Combinations or VEGF PD1 Inhibition as 1st Line Therapy for Advanced Clear Cell RCC VEGF PD1 Inhibition.pdf
Session 4 Second Line and Beyond.mp4
Session 4 Second Line and Beyond.pdf
Session 5 Biomarkers beyond PD-L1 in Bladder Cancer.mp4
Session 5 Biomarkers beyond PD-L1 in Bladder Cancer.pdf
Session 5 Circulating Biomarkers in Bladder and Kidneys Cancer.mp4
Session 5 Circulating Biomarkers in Bladder and Kidneys Cancer.pdf
Session 5 New Drugs in Bladder Cancer Beyond ADCs.mp4
Session 5 New Drugs in Bladder Cancer Beyond ADCs.pdf
Session 5 New Drugs in RCC Targeted, Immune and Cellular Therapies.mp4
Session 5 New Drugs in RCC Targeted, Immune and Cellular Therapies.pdf
Session 5 Personalized Therapy in RCC Fact or Fiction.mp4
Session 5 Personalized Therapy in RCC Fact or Fiction.pdf
Session 6 ADCs Present and Future in Bladder Cancer.mp4
Session 6 ADCs Present and Future in Bladder Cancer.pdf
Session 6 Can we Stop Targeted Therapy, Immune or ADC Therapy.mp4
Session 6 Can we Stop Targeted Therapy, Immune or ADC Therapy.pdf
Session 6 Optimising CTLA-4 in Renal and Bladder Cancer.mp4
Session 6 Optimising CTLA-4 in Renal and Bladder Cancer.pdf
Session 6 Participants Clinical Case Discussion Nausea and Ataxia in a Patient with Metastatic Clear Cell Renal Carcinoma Not as Clear as it Seems.mp4
Session 6 Participants Clinical Case Discussion Nausea and Ataxia in a Patient with Metastatic Clear Cell Renal Carcinoma Not as Clear as it Seems.pdf
Session 6 Participants Clinical Case Discussion Nephrectomy and Metastasectomy Post First Line Combination Immunotherapy for Metastatic Clear Cell RCC.mp4
Session 6 Participants Clinical Case Discussion Nephrectomy and Metastasectomy Post First Line Combination Immunotherapy for Metastatic Clear Cell RCC.pdf
Session 6 Participants Clinical Case Discussion The Role of Cytoreductive Nephrectomy in the Era of First-Line Immunotherapy for Metastatic Renal Cell Carcinoma.mp4
Session 6 Participants Clinical Case Discussion The Role of Cytoreductive Nephrectomy in the Era of First-Line Immunotherapy for Metastatic Renal Cell Carcinoma.pdf
Session 6 Treatment after Progression on Adjuvant Therapy in Renal and Bladder Cancer.mp4
Session 6 Treatment after Progression on Adjuvant Therapy in Renal and Bladder Cancer.pdf
Welcome from ESMO – Objectives and Scientific Introduction.mp4
Welcome from ESMO – Objectives and Scientific Introduction.pdf